Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab in systemic sclerosis
NL-OMON60281Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anifrolumab in systemic sclerosis (SSc) and interstitial lung disease (ILD), sponsored by AstraZeneca. Primary endpoint: Revised-CRISS-25 response. Started Jun 2024; status: active, not recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic sclerosis (SSc)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NL-OMON60281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60281.